AnodyneWiki

Solriamfetol

Solriamfetol
Solriamfetol
Salts
[]
Solriamfetol hydrochloride
Solriamfetol hydrochloride
Molecular structure drawn from PubChem coordinates
Physical properties
[]
Molecular mass194.23 g/mol [1]
Predicted LogP0.6 [1]
Structural Identifiers
[]
Molecular formulaC10H14N2O2
IUPAC name[(2R)-2-amino-3-phenylpropyl] carbamate
SMILESC1=CC=C(C=C1)C[C@H](COC(=O)N)N
InChIInChI=1S/C10H14N2O2/c11-9(7-14-10(12)13)6-8-4-2-1-3-5-8/h1-5,9H,6-7,11H2,(H2,12,13)/t9-/m1/s1
InChIKeyUCTRAOBQFUDCSR-SECBINFHSA-N
CAS number178429-62-4
UNII939U7C91AI
PubChem CID10130337
Pharmacokinetics[]
Elimination half-life~7.1 hours
MetabolismMinimal (~1%)
ExcretionUrine (95% unchanged)
Routes of administrationBy mouth

Solriamfetol (also known as (2R)-2-amino-3-phenylpropyl carbamate, Jzp-110, Ykp-10a, Adx-n-05, Skl-n-05, Benzenepropanol, β-amino-, carbamate (ester), (R)-, Benzenepropanol, β-amino-, carbamate (ester), (βR)-, R-228060, ((2R)-2-amino-3-phenylpropyl) carbamate or solriamfetolum) is a substance of the amphetamine class.

Chemistry

Salts []

Solriamfetol is typically found in the form of its hydrochloride salt.

 []

Solriamfetol is a single defined stereoisomer (optical activity ( + )).

Solriamfetol matches Lipinski's rule of five.

Pharmacology

Mechanism of action []

The specific mechanism of action is unknown but it may be through its activity as a dopamine and norepinephrine reuptake inhibitor. [1]

 []

  • Canada: Solriamfetol is Prescription only.[3][4]
  • United States: Solriamfetol is a Schedule IV under the "Controlled Substances Act".
  • European Union: Solriamfetol is Prescription only.
  • Other: Solriamfetol is a SE: Rx-only.[5]

See also []

External links []

References []

  1. National Center for Biotechnology Information. PubChem Compound Summary for CID 10130337, Solriamfetol. Accessed November 21, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/10130337
  2. U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Solriamfetol. UNII: 939U7C91AI. Global Substance Registration System. Accessed November 21, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/939U7C91AI
  3. Summary Basis of Decision (SBD) for Sunosi. Health Canada. 23 October 2014. https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00549&lang=en
  4. Health product highlights 2021: Annexes of products approved in 2021. Health Canada. 3 August 2022. https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/health-product-highlights-2021/appendices.html
  5. Sunosi, Filmdragerad tablett 75 mg. FASS. September 2023. https://fass.se/health/product/20181109000031/fass-text

Data sources []

SourceStatusUpdated (UTC)
dosingmissing (no dosing statistics)2026-11-20 12:01:21
drugspromissing (no DrugsPRO reagent data)2026-11-20 12:01:17
erowidmissing (no Erowid substance of that name)2026-11-20 12:01:17
gsrsok2026-11-20 12:01:18
hmdbmissing (no HMDB id)2026-11-20 12:01:17
keggok2026-11-20 12:01:20
pubchemok2026-11-20 12:01:17
redditmissing (no r/tripreports posts mention it)2026-11-20 12:01:17
sidermissing (not in SIDER)2026-11-20 12:01:17
structureok2026-11-20 12:01:17
wikipediaok2026-11-20 12:01:18